An embodiment of the present invention is directed to a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines comprising: a protein carrier comprising an inserted nucleic acid consensus sequence； at least one polysaccharide such as a capsular Gram-positive polysaccharide linked to the consensus sequence； and, optionally, an adjuvant or pharmaceutically acceptable carrier. In a further aspect, the instant invention is directed to methods of producing Gram-positive and other bioconjugate vaccines. In another aspect, an N- glycosylated protein is provided that comprises one or more polysaccharides such as Gram-positive polysaccharides. The present invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N- glycosylated protein and/or bioconjugate vaccine. Further, the invention is directed to methods of inducing an immune response in a mammal comprising administering said bioconjugate vaccines.
